Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Anticancer Drugs ; 18(9): 1093-101, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17704660

ABSTRACT

The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 patients were randomized to assay-directed therapy (n=94) or physician's-choice chemotherapy (n=86). Median follow-up at analysis was 18 months. Response was assessable in 147 patients: 31.5% achieved a partial or complete response in the physician's-choice group compared with 40.5% in the assay-directed group (26 versus 31% by intention-to-treat analysis respectively). Intention-to-treat analysis showed a median progression-free survival of 93 days in the physician's-choice group and 104 days in the assay-directed group (hazard ratio 0.8, 95% confidence interval 0.59-1.10, not significant). No difference was seen in overall survival between the groups, although 12/39 (41%) of patients who crossed over from the physician's-choice arm obtained a response. Increased use of combination therapy was seen in the physician's-choice arm during the study as a result of the observed effects of assay-directed therapy in patients. Patients entering the physician's-choice arm of the study during the first year did significantly worse than those who entered in the subsequent years (hazard ratio 0.44, 95% confidence interval 0.2-0.9, P<0.03). This small randomized clinical trial has documented a trend towards improved response and progression-free survival for assay-directed treatment. Chemosensitivity testing might provide useful information in some patients with ovarian cancer, although a larger trial is required to confirm this. The ATP-based tumour chemosensitivity assay remains an investigational method in this condition.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/therapeutic use , Cisplatin/pharmacology , Drug Resistance, Neoplasm/drug effects , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/drug therapy , Practice Patterns, Physicians' , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Disease-Free Survival , Drug Screening Assays, Antitumor , Female , Humans , Middle Aged , Neoplasm Recurrence, Local/mortality , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prospective Studies , Tumor Cells, Cultured
2.
Biophys J ; 90(10): 3783-95, 2006 May 15.
Article in English | MEDLINE | ID: mdl-16500983

ABSTRACT

The prostate gland is conventionally divided into zones or regions. This morphology is of clinical significance as prostate cancer (CaP) occurs mainly in the peripheral zone (PZ). We obtained tissue sets consisting of paraffin-embedded blocks of cancer-free transition zone (TZ) and PZ and adjacent CaP from patients (n = 6) who had undergone radical retropubic prostatectomy; a seventh tissue set of snap-frozen PZ and TZ was obtained from a CaP-free gland removed after radical cystoprostatectomy. Paraffin-embedded tissue slices were sectioned (10-mum thick) and mounted on suitable windows to facilitate infrared (IR) spectra acquisition before being dewaxed and air dried; cryosections were dessicated on BaF(2) windows. Spectra were collected employing synchrotron Fourier-transform infrared (FTIR) microspectroscopy in transmission mode or attenuated total reflection-FTIR (ATR) spectroscopy. Epithelial cell and stromal IR spectra were subjected to principal component analysis to determine whether wavenumber-absorbance relationships expressed as single points in "hyperspace" might on the basis of multivariate distance reveal biophysical differences between cells in situ in different tissue regions. After spectroscopic analysis, plotted clusters and their loadings curves highlighted marked variation in the spectral region containing DNA/RNA bands ( approximately 1490-1000 cm(-1)). By interrogating the intrinsic dimensionality of IR spectra in this small cohort sample, we found that TZ epithelial cells appeared to align more closely with those of CaP while exhibiting marked structural differences compared to PZ epithelium. IR spectra of PZ stroma also suggested that these cells are structurally more different to CaP than those located in the TZ. Because the PZ exhibits a higher occurrence of CaP, other factors (e.g., hormone exposure) may modulate the growth kinetics of initiated epithelial cells in this region. The results of this pilot study surprisingly indicate that TZ epithelial cells are more likely to exhibit what may be a susceptibility-to-adenocarcinoma spectral signature. Thus, IR spectroscopy on its own may not be sufficient to identify premalignant prostate epithelial cells most likely to progress to CaP.


Subject(s)
Biomarkers, Tumor/analysis , Precancerous Conditions/pathology , Prostate/metabolism , Prostate/pathology , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Spectrophotometry, Infrared/methods , Algorithms , Cells, Cultured , Diagnosis, Computer-Assisted/methods , Feasibility Studies , Humans , Male , Multivariate Analysis , Pilot Projects , Precancerous Conditions/chemistry , Reproducibility of Results , Sensitivity and Specificity
3.
Cancer Lett ; 242(1): 88-94, 2006 Oct 08.
Article in English | MEDLINE | ID: mdl-16338069

ABSTRACT

Epidemiological studies suggest that environment plays an important role in the aetiology of cancer. Thus, if a cancer (e.g. prostate cancer (CaP)) arises in males, one could hypothesize that risk in co-habiting partners might be elevated. We conducted an observational-questionnaire study in NorthWest England evaluating the medical histories of CaP males and their female partners. Details regarding previous partners (>10y) were also sought. Self-filled questionnaires were obtained from 548 males, 81 of whom provided information on previous female partners (PFPs) and 448 current female partners (CFPs). Observed rates over a 30-y period (1971-2001) of common cancers (breast, colorectal or lung) in female partners and colorectal cancer in males were compared to the cumulative expected probability (estimated using crude incidence rates for England provided by the Office of National Statistics, UK) using a Chi-Square Goodness-of-Fit test. Colorectal cancers in males were similar to national estimates. Rates for breast, colorectal or lung cancer among CFPs and the total female cohort (CFPs plus PFPs) were also similar to estimates. However, observed rates for breast or lung cancers among PFPs were significantly (P< or =0.001) elevated. Our results suggest no evidence of elevated risk among female partners of CaP males.


Subject(s)
Family Health , Neoplasms/epidemiology , Prostatic Neoplasms/pathology , Aged , Aged, 80 and over , Cohort Studies , Environmental Exposure , Female , Humans , Male , Middle Aged , Models, Statistical , Neoplasms/etiology , Prostatic Neoplasms/etiology , Smoking , Surveys and Questionnaires , United Kingdom
4.
Cancer Lett ; 215(1): 69-78, 2004 Nov 08.
Article in English | MEDLINE | ID: mdl-15374634

ABSTRACT

Prostate cancer (CaP) mostly occurs in the peripheral zone whereas benign prostatic hypertrophy (BPH) occurs in the transition zone. Human prostates (n = 12) were obtained, with ethical approval, from radical retropubic prostatectomies. Following resection, tissue sets consisting of peripheral zone and transition zone were isolated from a lobe pre-operatively identified as negative for CaP. Real-time RT-PCR was employed to quantitatively examine CYP1A1, CYP1A2 and CYP1B1. Quantifiable CYP1A1 expression was observed (in nine out of twelve tissue sets) whilst CYP1A2 mRNA transcripts, although detectable (in six out of twelve tissue sets), were unquantifiable. In ten tissue sets, 2- to 6-fold higher CYP1B1 expression in peripheral zone as compared to transition zone was observed. In the other two, equal CYP1B1 expression levels were observed; retrospective examination identified malignancy in one of the zones. Inter-individual variations (up to 10-fold) in CYP1B1 were also noted. Immunohistochemistry for CYP1B1 showed epithelial and stromal nuclear staining. Since CYP1B1 metabolises hormones and carcinogens our results, if confirmed, suggest that this enzyme may influence susceptibility to CaP.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Prostate/enzymology , Prostatic Neoplasms/enzymology , Aged , Aryl Hydrocarbon Hydroxylases/genetics , Cell Nucleus/enzymology , Cytochrome P-450 CYP1A1/genetics , Cytochrome P-450 CYP1A1/metabolism , Cytochrome P-450 CYP1A2/genetics , Cytochrome P-450 CYP1A2/metabolism , Cytochrome P-450 CYP1B1 , Epithelial Cells/enzymology , Epithelial Cells/pathology , Humans , Male , Middle Aged , Prostate/pathology , Prostate/ultrastructure , Prostatectomy , Prostatic Hyperplasia/enzymology , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/pathology , Prostatic Neoplasms/ultrastructure , RNA, Messenger , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Stromal Cells/enzymology , Stromal Cells/pathology
5.
BMC Cancer ; 3: 19, 2003 Jul 03.
Article in English | MEDLINE | ID: mdl-12841853

ABSTRACT

BACKGROUND: We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints. METHODS: From November 1998 to November 2001, 46 patients with pre-treated, advanced ovarian cancer were given a total of 56 courses of chemotherapy based on in-vitro ATP-TCA responses obtained from fresh tumor samples or ascites. Forty-four patients were evaluable for results. Of these, 18 patients had clinically platinum resistant disease (relapse < 6 months after first course of chemotherapy). There was evidence of cisplatin resistance in 31 patients from their first ATP-TCA. Response to treatment was assessed by radiology, clinical assessment and tumor marker level (CA 125). RESULTS: The overall response rate was 59% (33/56) per course of chemotherapy, including 12 complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease. Two patients were not evaluable for response having received just one cycle of chemotherapy: if these were excluded the response rate is 61%. Fifteen patients are still alive. Median progression free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for each patient following the start of TCA-directed therapy was 10.4 months (95% confidence interval 7.9-12.8 months). CONCLUSION: The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight to the reproducibility of results from different centres.


Subject(s)
Drug Screening Assays, Antitumor/methods , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/drug therapy , Salvage Therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Resistance, Neoplasm , Female , Humans , Reproducibility of Results , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...